The Criteria documents on this page include VHA Pharmacy Benefits
Management (PBM) and Medical Advisory Panel (MAP) Criteria for Use documents.
| Criteria |
| Adefovir, Criteria for Use |
| Alatrofloxacin/Trovafloxacin, Criteria for Non-Formulary Use |
| Angiotensin II Receptor Antagonists (AIIRAs), Criteria for Use |
| Becaplermin, Criteria for Non-Formulary Use |
| Beta-Adrenergic Blockers |
| Biologic, Criteria for Non-Formulary Use |
| Buprenorphine, Criteria for Non-Formulary Use |
| Clinically Uroselective Alpha Adrenergic Blockers, Criteria for Non-Formulary Use |
UNDER REVISION:
COX2, Criteria for Non-Formulary Use
Summary of COX-2
Colon CA, NSAIDs &COX2s
|
| Dihydropyridine Calcium Antagonists, Criteria for Use |
Drotrecogin Alfa, Criteria for Use
Drotrecogin Alfa Checklist |
| Fondaparinux, Criteria for Use |
| Gatifloxacin, Criteria for Non-Formulary Use |
| Highly Teratogenic Retinoids and High-dose Vitamin A, Criteria for use |
| Imatinib |
| Inhaled Insulin, Criteria for Non-formulary Use |
| Insulin Glargine, Criteria for Non-formulary Use |
| UNDER REVISION: Lansoprazole BID Dosing, Criteria for Use |
| Omacor, Criteria for Non-formulary Use |
| Omalizumab, Criteria for Non-formulary Use |
Oxycodone CR
Treatment Algorithm |
| Pegylated Interferon, Criteria for Use |
| Pharmaceutical Selection of Antiplatelet Therapy in Cerebrovascular Disease, Criteria for Use |
| Pregabalin,
Criteria for Use |
| Quinine Sulfate, Criteria for Non-Formulary Use |
| Quinupristin/dalfopristin, Criteria for Use |
| Ramipril, Criteria for Use |
| Sevelamer, Criteria for Use |
| Sitagliptin, Criteria for Use |
| Statin Criteria for Use (Fluvastatin/Pravastatin/Atorvastatin) |
| Tamsulosin, Criteria for Non-Formulary Use |
| Tegaserod, Criteria for Non-Formulary Use |
| Thiazolidinediones (Risiglitazone, Pioglitazone) Criteria for Non-Formulary Use |
| Tiotropium Criteria for Use |
| TZD (Thiazolidinediones, Rosiglitazone, Pioglitazone) Criteria for Use |
